BRCA2 promoter hypermethylation as a biomarker for the leukemic transformation of myeloproliferative neoplasms
figureposted on 2022-03-09, 09:22 authored by Zhiyuan Wu, Gusheng Tang, Ming Guan, Bin Wang, Xuemei Tang, Qingyun Zhang, Can Yang
Supplementary table 1. Probes flanking the promoter region of 236 DDR genes retained for differential methylation analysis
Supplementary table 2. MPN and methylation analysis
Supplementary Figure 1 Differential methylation analysis revealed HR gene promoter methylation in MPNs-LT
A) Flow chat illustrating the pipeline of differential methylation analysis in 241 DDR genes.
B) Bisulfite treatment and qPCR quantification of RAD50, POLD1, TOP3B and FEN1 promoter methylation in an in-house cohort of 5 MPNs-LT, 75 cMPNs, and 50 healthy donors (two-sample t-test, ***P < 0.001, ****P < 0.0001, n.s. not significant).
Supplementary Figure 2 Single base substitution mutational signature in cMPNs and MPNs-LT
A) Comparison of mutational signature 1 (aging), 5 (transcriptional strand T>C substitutions), 6 (mismatch repair deficiency), 12 (unknown aetiology), 20 (mismatch repair deficiency), and 21 (unknown aetiology) between cMPNs and MPNs-LT. (two-sample t-test, *P < 0.05, n.s. not significant).
B) Correlation between mutational signature 5 and signature 3 in the in-house MPNs cohort.
Molecular mechanism and clinical detection of NBN gene amplification leading to chemotherapy drug resistance in ovarian cancer
National Natural Science Foundation of ChinaFind out more...